Immunosuppressant drugs (ISDs) are routinely used in clinical practice to maintain organ
transplant survival. However, these drugs are characterized by a restricted therapeutic …

Kidney transplantation is the preferred therapeutic option for end-stage kidney disease, but,
despite major therapeutic advancements, allograft rejection continues to endanger graft …

Tailoring of immunosuppressive drug therapy to the specific requirements of the individual
patient to optimize efficacy and minimize toxicity remains one of the biggest challenges in …

Cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil are the primary
immunosuppressants used on pediatric organ transplantation. Therapeutic drug monitoring …

Background: Tacrolimus (TAC) and mycophenolic acid (MPA) are the main
immunosuppressive drugs used in pediatric kidney transplantation. Single nucleotide …

Every month, new releases on the relationship between pharmacogenetic biomarkers and
immunosuppressive drug therapy in kidney transplantation are published. However, the …

With the advent of new immunosuppressants and formulations, the elucidation of molecular
targets and the evolution of therapeutic drug monitoring, the field of organ transplantation …

Advances in the management of patients after solid organ transplantation have led to
dramatic decreases in rates of acute rejection, but long-term graft and patient survival have …

Transplant recipients receive potent immunosuppressive drugs in order to prevent graft
rejection. Therapeutic drug monitoring is the current approach to guide the dosing of …

Implementation of pharmacogenetics in transplantation medicine has not met the
expectations expressed 15 years ago. Numerous studies have reported associations …